Gelesis Holdings Debt to Equity Ratio 2021-2022 | GLS
Current and historical debt to equity ratio values for Gelesis Holdings (GLS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Gelesis Holdings debt/equity for the three months ending September 30, 2022 was 5.89.
| Gelesis Holdings Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-09-30 |
$0.13B |
$-0.00B |
-37.31 |
| 2022-06-30 |
$0.13B |
$0.01B |
26.26 |
| 2022-03-31 |
$0.14B |
$0.01B |
14.23 |
| 2021-12-31 |
$0.48B |
$-0.33B |
-1.44 |
| 2021-09-30 |
$0.32B |
$-0.04B |
-7.24 |
| 2021-06-30 |
$0.27B |
$0.01B |
54.40 |
| 2021-03-31 |
$0.27B |
$0.01B |
54.43 |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.27B |
$0.01B |
54.47 |
| 2020-06-30 |
$0.00B |
$0.00B |
8.87 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.012B |
$0.011B |
|
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
|
